BTAIBioXcel Therapeutics, Inc.
The schedule
- Wed30Sep
Expected clinical update or milestone regarding the Alzheimer's agitation pipeline.
- Thu15Oct
Deadline to regain Nasdaq minimum bid price compliance, likely triggering a reverse stock split.
- Tue17Nov
FDA PDUFA target action date for the supplemental New Drug Application of IGALMI for at-home use.
- Mon8Feb
Q3 results and initial commentary on the expected 2027 cash burn profile.
- Fri7May
Year-end financial results and a mandatory conclusion to the prolonged strategic review.
- Fri14May
First quarter fiscal 2027 earnings reflecting ongoing survival efforts.
Past
- Tue11Aug
Actual outcome: Bear
BioXcel Therapeutics reported Q2 results that missed revenue estimates, despite narrowing its loss per share year-over-year. The lack of positive revenue surprises, combined with ongoing concerns over the company's critically low cash runway and strategic alternative review, drove the stock down 13.7% following the release.
Quarterly financial results focusing on the critically low cash runway and ongoing strategic alternative review.
- Wed15Jul
Actual outcome: Bear · $0.80 at outcome
The stock declined 12.9% as BTAI's severe liquidity constraints and $100.28 million debt burden remained unresolved during the period. Without a definitive, non-dilutive balance sheet action, the market continued to price in the high probability of toxic financing or restructuring, driving shares lower on fears of significant shareholder dilution.
Imminent risk of toxic financing or restructuring as BTAI navigates $100.28M in debt against rapidly depleting cash reserves.
- Fri15May
Actual outcome: Bear · $1.07 at outcome
Stock fell 6.1% from event to outcome date, aligning with the bear trajectory.
The Q1 2026 earnings call will update the market on IGALMI uptake, R&D spend on BXCL501 and other pipeline assets, and—critically—cash runway given BTAI’s negative equity and high debt load. With the stock at $1.02 and deeply oversold, any evidence of disciplined expense control or extended runway could support a rebound toward $1.30, while continued high burn with limited revenue traction risks a breakdown toward $1.30.
